Polgar, Stephen, Karimi, Leila, Buultjens, Melissa, Morris, Megan E. and Busse-Morris, Monica ![]() |
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution Non-commercial. Download (113kB) | Preview |
Abstract
Background: Evidence from a growing number of preclinical studies indicate that recently discovered stem cell lines may be translated into viable cellular therapies for people with Parkinson’s disease. Objectives: In a brief but critical review, we examine the use of primary and secondary outcome measures currently used to evaluate the efficacy of cellular therapies. Methods: The current practice of relying on a single primary outcome measure does not appear to provide the evidence required for demonstrating the robust, life-changing recovery anticipated with the successful implementation of cellular therapies. Results: We propose a 360-degree assessment protocol, which includes co-primary and composite outcome measures to provide accurate and comprehensive evidence of treatment efficacy, from the perspectives of both the researchers and the patients.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine |
Publisher: | IOS Press |
ISSN: | 1877-7171 |
Date of First Compliant Deposit: | 29 June 2018 |
Date of Acceptance: | 17 April 2018 |
Last Modified: | 05 May 2023 16:01 |
URI: | https://orca.cardiff.ac.uk/id/eprint/112892 |
Citation Data
Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |